Unit:
Κατεύθυνση Κλινικές Μελέτες: Σχεδιασμός και ΕκτέλεσηLibrary of the School of Health Sciences
Author:
Kikakis Emmanouil
Supervisors info:
Κωνσταντόπουλος Κωνσταντίνος, Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Τέρπος Ευάγγελος, Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Ευστάθιος Καστρίτης, Αναπληρωτής Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Original Title:
Ο ρόλος του Kalydeco (Ivacaftor) στην αντιμετώπιση της κυστικής ίνωσης: Συστηματική ανασκόπηση
Translated title:
The role of Kalydeco (Ivacaftor) in the treatment of cystic fibrosis: A systematic review
Summary:
Cystic fibrosis is an hereditary disease caused by mutations in the gene regulating
transmembrane conduction cystic fibrosis Although cystic fibrosis is an autoimmune
disease, its phenotypic variability is significant - as seen by the wide range of patients
with severity of the disease the same genotype. Kalydeco tablets are indicated for the
treatment of adults, adolescents and children aged 6 years and over and weighing 25
kg or more with cystic fibrosis (KI) who have one of the following mutations
(category III) in the CFTR gene. Approval in 2012 for the drug Cystic fibrosis
Kalydeco® (Ivacaftor), marked a significant advance in the treatment of KI because
it is the first drug that targets the mechanism of the disease and not its symptoms.
Based on the above, this work studies the above, both through a bibliographic review
and through a systematic review.
Main subject category:
Health Sciences
Keywords:
Kalydeco, Ivacaftor, Cystic fybrosis
